The Study
15-PGDH Inhibition Overcomes Muscle Regenerative Deficit Seen With GLP1-Receptor Agonist–Induced Weight Loss
This study tested two drugs in mice to see if one could fix muscle problems caused by the other. It found that when mice got both drugs, their muscles healed better after injury. But this doesn't mean it will work the same way in people — it's like saying a toy car works on a track, so a real car will too.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
A diet pill called semaglutide helps mice lose fat, but it also makes their muscles weaker when they get hurt. A second pill that boosts a natural muscle-repair chemical fixes this problem.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 516 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — this suggests people on weight-loss drugs like semaglutide might recover better from injuries or exercise if they also take a muscle-repair booster.
- 2Semaglutide alone reduced muscle mass by 15–20% and slowed muscle repair after injury.
- 3Adding the 15-PGDH inhibitor restored muscle strength recovery by 30–40% and doubled muscle stem cell growth.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
bioRxiv
Year
2026
Authors
Minas Nalbandian, Jameel Lone, Emmeran Le Moal, Ireh Kim, Y. Li, Peggy Kraft, Meng Zhao, Kassie Kolacar, Zeyuan Zhang, Katrin J. Svensson, Helen M. Blau
Related Content
Claims (8)
Blocking the enzyme 15-PGDH prevents the loss of skeletal muscle mass and strength in mice receiving semaglutide.
In mice given semaglutide, blocking the enzyme 15-PGDH leads to 30% more preservation of lean body mass than in mice not given any treatment.
In obese mice receiving semaglutide, blocking the enzyme 15-hydroxyprostaglandin dehydrogenase increases muscle stem cell proliferation, leading to improved muscle repair and strength recovery after injury, while not reducing the weight loss caused by semaglutide.
In obese mice, semaglutide causes a 15–20% reduction in skeletal muscle mass while leaving maximal muscle strength unchanged during steady-state conditions.
In obese mice, semaglutide reduces the proliferation of muscle stem cells after injury, leading to smaller regenerating muscle fibers; this effect is reversed when a 15-PGDH inhibitor is administered to restore PGE2 signaling and stem cell activity.
In obese mice, combining a 15-PGDH inhibitor with semaglutide increases muscle strength recovery after injury by 30–40% compared to semaglutide alone, while maintaining the same reductions in body fat and improvements in glucose levels.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.